#pharming-group

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Pharming Group reported a 21% increase in third-quarter 2026 total revenues to $117.6 million, beating market estimates on the back of strong RUCONEST demand. The biotechnology firm also highlighted ongoing pipeline expansions and upcoming topline data releases.